Katie L Alexander1, Qing Zhao1, Meagan Reif1, Alexander F Rosenberg2, Peter J Mannon3, Lennard Wayne Duck1, Charles O Elson4. 1. Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 2. Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama; Informatics Institute, University of Alabama at Birmingham, Birmingham, Alabama. 3. Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Birmingham Veterans Affairs Medical Center, Medical Service, Birmingham, Alabama. 4. Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: coelson@uabmc.edu.
Abstract
BACKGROUND AND AIMS: Crohn's disease and ulcerative colitis are characterized by dysregulated adaptive immune responses to the microbiota in genetically susceptible individuals, but the specificity of these responses remains largely undefined. Therefore, we developed a microbiota antigen microarray to characterize microbial antibody reactivity, particularly to human-derived microbiota flagellins, in inflammatory bowel disease. METHODS: Sera from healthy volunteers (n = 87) at the University of Alabama at Birmingham and from patients recruited from the Kirklin Clinic of University of Alabama at Birmingham Hospital, including patients with Crohn's disease (n = 152) and ulcerative colitis (n = 170), were individually probed against microbiota bacterial flagellins of both mouse and human origin and analyzed for IgG and IgA antibody responses. Circulating flagellin-reactive T effector (CD4+CD154+) and T regulatory (CD4+CD137+) cells were isolated and evaluated in selected patients. Resulting adaptive immune responses were compared with corresponding clinical data to determine relevancy to disease behavior. RESULTS: We show that patients with IBD express selective patterns of antibody reactivity to microbiota flagellins. Patients with Crohn's disease, but not patients with ulcerative colitis, display augmented serum IgG to human ileal-localized Lachnospiraceae flagellins, with a subset of patients having high responses to more than 10 flagellins. Elevated responses to CBir1, a mouse Lachnospiraceae flagellin used clinically to diagnose CD, correlated with multi-Lachnospiraceae flagellin reactivity. In this subset of patients with CD, multi-flagellin reactivity was associated with elevated flagellin-specific CD154+CD45RA- T memory cells, a reduced ratio of flagellin-reactive CD4+ T regulatory to T effector cells, and a high frequency of disease complications. CONCLUSIONS: Patients with Crohn's disease display strong adaptive immune response to human-derived Lachnospiraceae flagellins, which may be targeted for prognosis and future personalized therapies.
BACKGROUND AND AIMS: Crohn's disease and ulcerative colitis are characterized by dysregulated adaptive immune responses to the microbiota in genetically susceptible individuals, but the specificity of these responses remains largely undefined. Therefore, we developed a microbiota antigen microarray to characterize microbial antibody reactivity, particularly to human-derived microbiota flagellins, in inflammatory bowel disease. METHODS: Sera from healthy volunteers (n = 87) at the University of Alabama at Birmingham and from patients recruited from the Kirklin Clinic of University of Alabama at Birmingham Hospital, including patients with Crohn's disease (n = 152) and ulcerative colitis (n = 170), were individually probed against microbiota bacterial flagellins of both mouse and human origin and analyzed for IgG and IgA antibody responses. Circulating flagellin-reactive T effector (CD4+CD154+) and T regulatory (CD4+CD137+) cells were isolated and evaluated in selected patients. Resulting adaptive immune responses were compared with corresponding clinical data to determine relevancy to disease behavior. RESULTS: We show that patients with IBD express selective patterns of antibody reactivity to microbiota flagellins. Patients with Crohn's disease, but not patients with ulcerative colitis, display augmented serum IgG to human ileal-localized Lachnospiraceae flagellins, with a subset of patients having high responses to more than 10 flagellins. Elevated responses to CBir1, a mouse Lachnospiraceae flagellin used clinically to diagnose CD, correlated with multi-Lachnospiraceae flagellin reactivity. In this subset of patients with CD, multi-flagellin reactivity was associated with elevated flagellin-specific CD154+CD45RA- T memory cells, a reduced ratio of flagellin-reactive CD4+ T regulatory to T effector cells, and a high frequency of disease complications. CONCLUSIONS: Patients with Crohn's disease display strong adaptive immune response to human-derived Lachnospiraceae flagellins, which may be targeted for prognosis and future personalized therapies.
Authors: M Camus; S Esses; B Pariente; L Le Bourhis; C Douay; V Chardiny; I Mocan; K Benlagha; E Clave; A Toubert; L Mayer; M Allez Journal: Mucosal Immunol Date: 2013-08-14 Impact factor: 7.313
Authors: Matthew T Sorbara; Eric R Littmann; Emily Fontana; Thomas U Moody; Claire E Kohout; Mergim Gjonbalaj; Vincent Eaton; Ruth Seok; Ingrid M Leiner; Eric G Pamer Journal: Cell Host Microbe Date: 2020-06-02 Impact factor: 21.023
Authors: Pieter Van den Abbeele; Clara Belzer; Margot Goossens; Michiel Kleerebezem; Willem M De Vos; Olivier Thas; Rosemarie De Weirdt; Frederiek-Maarten Kerckhof; Tom Van de Wiele Journal: ISME J Date: 2012-12-13 Impact factor: 10.302
Authors: Subra Kugathasan; Lee A Denson; Thomas D Walters; Mi-Ok Kim; Urko M Marigorta; Melanie Schirmer; Kajari Mondal; Chunyan Liu; Anne Griffiths; Joshua D Noe; Wallace V Crandall; Scott Snapper; Shervin Rabizadeh; Joel R Rosh; Jason M Shapiro; Stephen Guthery; David R Mack; Richard Kellermayer; Michael D Kappelman; Steven Steiner; Dedrick E Moulton; David Keljo; Stanley Cohen; Maria Oliva-Hemker; Melvin B Heyman; Anthony R Otley; Susan S Baker; Jonathan S Evans; Barbara S Kirschner; Ashish S Patel; David Ziring; Bruce C Trapnell; Francisco A Sylvester; Michael C Stephens; Robert N Baldassano; James F Markowitz; Judy Cho; Ramnik J Xavier; Curtis Huttenhower; Bruce J Aronow; Greg Gibson; Jeffrey S Hyams; Marla C Dubinsky Journal: Lancet Date: 2017-03-02 Impact factor: 79.321
Authors: Malin E V Johansson; Jenny K Gustafsson; Jessica Holmén-Larsson; Karolina S Jabbar; Lijun Xia; Hua Xu; Fayez K Ghishan; Frederic A Carvalho; Andrew T Gewirtz; Henrik Sjövall; Gunnar C Hansson Journal: Gut Date: 2013-02-20 Impact factor: 23.059
Authors: Arno R Bourgonje; Geesje Roo-Brand; Paola Lisotto; Mehdi Sadaghian Sadabad; Rosanne D Reitsema; Marcus C de Goffau; Klaas Nico Faber; Gerard Dijkstra; Hermie J M Harmsen Journal: Front Immunol Date: 2022-05-25 Impact factor: 8.786
Authors: Dagmar Schierova; Radka Roubalova; Martin Kolar; Zuzana Stehlikova; Filip Rob; Zuzana Jackova; Stepan Coufal; Tomas Thon; Martin Mihula; Martin Modrak; Miloslav Kverka; Lukas Bajer; Klara Kostovcikova; Pavel Drastich; Jana Hercogova; Michaela Novakova; Martin Vasatko; Milan Lukas; Helena Tlaskalova-Hogenova; Zuzana Jiraskova Zakostelska Journal: Cells Date: 2021-11-16 Impact factor: 6.600